Agios Pharmaceuticals, Inc. (AGIO)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $1.97B
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Latest financial period: June 30, 2026
Filed with the SEC: July 30, 2026
Estimated earnings date: October 29, 2026
Profit #1169 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 18.5% | 19.1% | 20.3% | 21.7% |
Growth #231 of 1484 companies
Payout #1117 of 1484 companies
Safety #704 of 1484 companies
Price #1472 of 1484 companies
